The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression.
Depression is related to the alterations of the central serotonergic system and some antidepressants achieve their therapeutic effects through alteration of serotonin (5-HT) (re)uptake. Peripheral biochemical markers, platelet and serum 5-HT concentrations, platelet monoamine oxidase (MAO) activity, plasma levels of cortisol and prolactin (PRL), were investigated in patients with major depression before and after 4 weeks of treatment with paroxetine (an inhibitor of 5-HT uptake) or tianeptine (a stimulator of 5-HT uptake). Study was open, single center and included female depressed patients, 21 treated with tianeptine (37.5 mg/day) and 15 treated with paroxetine (20 mg/day), and 11 drug-free healthy women (controls). Before treatment, depressed patients as a group had significantly higher serum 5-HT and cortisol concentrations than healthy controls. There were no differences in the other biochemical markers. Response to antidepressant treatment was estimated according to the 50% fall in the initial scores of Hamilton Depression Rating Scale (HAMD) after 4 weeks of treatment. Good therapeutic response was observed in 47% and 45% patients treated with paroxetine and tianeptine, respectively. Paroxetine treatment induced significant decrease in platelet 5-HT concentrations in both responders and nonresponders, while no alterations in platelet 5-HT values were found in tianeptine-treated patients. There was a subgroup of depressed patients in paroxetine-treated group with high pretreatment platelet 5-HT concentration and later poor therapeutic response to paroxetine treatment. Serum 5-HT values, platelet MAO activity or plasma cortisol or PRL levels were unchanged after both treatments. The results suggest that pretreatment platelet 5-HT levels, but not other peripheral biochemical markers, might predict therapeutic outcome at least in paroxetine-treated patients.
Mück-Seler
Dorotea
D
Ruder Bosković Institute, Division of Molecular Medicine, PO Box 180, HR-10002 Zagreb, Croatia. seler@rudjer.irb.hr
Pivac
Nela
N
Sagud
Marina
M
Jakovljević
Miro
M
Mihaljević-Peles
Alma
A
D000328:Adult; D000368:Aged; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology*; D015415:Biomarkers / Q000032:analysis*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000097:blood / Q000494:pharmacology; D017374:Paroxetine / Q000494:pharmacology*; D011237:Predictive Value of Tests; D011388:Prolactin / Q000097:blood; D012701:Serotonin / Q000097:blood; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D012720:Severity of Illness Index; D013841:Thiazepines / Q000494:pharmacology*; D016896:Treatment Outcome
D000929:Antidepressive Agents, Tricyclic; D015415:Biomarkers; D006854:Hydrocortisone; D008995:Monoamine Oxidase; D017374:Paroxetine; D011388:Prolactin; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D013841:Thiazepines; C050504:tianeptine